EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Nomenclature on Immune‐Mediated Drug Reactions: An EAACI Position Paper

Maria J Torres iD, Cristobalina Mayorga iD, Elizabeth J Phillips iD, Adriana Ariza iD, Annick Barbaud iD, Patrizia Bonadonna iD, Mariana Castells, Gülfem Çelik iD, Knut Brockow iD, Lene H Garvey iD, Inmaculada Doña iD, Jean-Christoph Caubet iD und 8 weitere

Allergy · 17.08.2026

DOI: 10.1111/all.70480 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergy, online erschienen am 17.08.2026. Verfasst von Maria J Torres und 19 weiteren Autor:innen. Beteiligte Einrichtung: Precision Allergy Translational Hub (PATH), IBIMA-Plataforma BIONAND, Málaga, Spain. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Academy of Allergy and Clinical Immunology (EAACI), Funding for open access charge: Universidad de Málaga/CBUA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over the past several decades, there have been significant advances in our understanding of both immunological and pharmacological mechanisms of adverse drug reactions (ADRs). Immune‐mediated drug reactions (IMDRs) represent a small proportion of ADRs and are caused by a pathological activation of the immune system or inflammatory pathways. Drugs can act as an antigen or may directly interact with the immune system or inflammatory pathways, making immune‐mediated drug reactions observed in contemporary practice not sufficiently explained by the Gell and Coombs (G&C) framework. Moreover, the phenotype alone is neither pathognomonic nor sufficient to infer the endotype. The proposed nomenclature integrates chrono‐morphological phenotypes, mechanistic endotypes and characteristics of the involved drug. In this nomenclature, IMDRs are classified, according to the nature of interaction with the immune system, in: (i) drug allergy that encompasses antigen‐driven reactions—diagnosed by tests detecting sensitisation—and (ii) drug hypersensitivity that includes the heterogeneous broad group of drug‐directly‐driven reactions. This framework supports precision medicine, aligns terminology with mechanisms, and provides a common language for interdisciplinary communication, pharmacovigilance, and drug development. It accommodates emerging therapeutic classes and remains adaptable to future discoveries in immunopathogenesis and biomarker development.

Schlagwörter

Stichwörter der Autor:innen

drugendotypeimmune‐mediated reactionsnomenclaturephenotype

Autor:innen und Institutionen

  • Precision Allergy Translational Hub (PATH), IBIMA-Plataforma BIONAND, Málaga, Spain.
  • Department of Medicine and Dermatology, Faculty of Medicine, Universidad de Málaga, Málaga, Spain.
  • Allergy Unit, Hospital Regional Universitario de Málaga, Málaga, Spain.
  • Center for Drug Safety and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Département de Dermatologie et Allergologie, Hôpital Tenon, AP-HP.Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, Sorbonne Université, Paris, France.
  • Allergy Unit, University Hospital of Verona, Policlinico G.B. Rossi, Verona, Italy.

ORCID-Profile: Maria J Torres, Cristobalina Mayorga, Elizabeth J Phillips, Adriana Ariza, Annick Barbaud, Patrizia Bonadonna, Gülfem Çelik, Knut Brockow, Lene H Garvey, Inmaculada Doña, Jean-Christoph Caubet, Francesca Mori, Jason Trubiano, Giorgia Marta, Antonino Romano, Ingrid Terreehorst, Asli Gelincik, Philip H Li, Vito Sabato

Förderung

  • European Academy of Allergy and Clinical Immunology (EAACI)
  • Funding for open access charge: Universidad de Málaga/CBUA

Zitieren

APA

Torres, M. J., Mayorga, C., Phillips, E. J., Ariza, A., Barbaud, A., Bonadonna, P., Castells, M., Çelik, G., Brockow, K., Garvey, L. H., Doña, I., Caubet, J. C., Mori, F., Trubiano, J., Marta, G., Romano, A., Terreehorst, I., Gelincik, A., Li, P. H., & Sabato, V. (2026). Nomenclature on Immune‐Mediated Drug Reactions: An EAACI Position Paper. Allergy. https://doi.org/10.1111/all.70480

Vancouver

Torres MJ, Mayorga C, Phillips EJ, Ariza A, Barbaud A, Bonadonna P, et al. Nomenclature on Immune‐Mediated Drug Reactions: An EAACI Position Paper. Allergy. 2026. doi:10.1111/all.70480

BibTeX
@article{Torres2026,
  author = {Torres, Maria J and Mayorga, Cristobalina and Phillips, Elizabeth J and Ariza, Adriana and Barbaud, Annick and Bonadonna, Patrizia and Castells, Mariana and Çelik, Gülfem and Brockow, Knut and Garvey, Lene H and Doña, Inmaculada and Caubet, Jean-Christoph and Mori, Francesca and Trubiano, Jason and Marta, Giorgia and Romano, Antonino and Terreehorst, Ingrid and Gelincik, Asli and Li, Philip H and Sabato, Vito},
  title = {Nomenclature on Immune‐Mediated Drug Reactions: An EAACI Position Paper},
  journal = {Allergy},
  year = {2026},
  doi = {10.1111/all.70480}
}
Kostenlos starten →